Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:CNTA NASDAQ:IMVT NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.91+1.9%$9.23$5.22▼$14.44$763.99M0.831.13 million shs248,352 shsCNTACentessa Pharmaceuticals$24.21+0.3%$20.83$9.60▼$24.81$3.25B1.571.02 million shs61,708 shsIMVTImmunovant$18.94+1.1%$16.19$12.72▼$32.10$3.30B0.481.52 million shs135,743 shsTARSTarsus Pharmaceuticals$67.55-1.1%$60.14$38.51▼$76.81$2.87B0.81661,096 shs182,105 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-6.52%-3.00%+2.70%-27.95%+62.15%CNTACentessa Pharmaceuticals+3.69%+5.60%+3.43%+56.65%+59.34%IMVTImmunovant-0.85%+7.64%+25.77%+10.56%-37.57%TARSTarsus Pharmaceuticals-0.55%-8.87%+22.81%+64.63%+75.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.91+1.9%$9.23$5.22▼$14.44$763.99M0.831.13 million shs248,352 shsCNTACentessa Pharmaceuticals$24.21+0.3%$20.83$9.60▼$24.81$3.25B1.571.02 million shs61,708 shsIMVTImmunovant$18.94+1.1%$16.19$12.72▼$32.10$3.30B0.481.52 million shs135,743 shsTARSTarsus Pharmaceuticals$67.55-1.1%$60.14$38.51▼$76.81$2.87B0.81661,096 shs182,105 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-6.52%-3.00%+2.70%-27.95%+62.15%CNTACentessa Pharmaceuticals+3.69%+5.60%+3.43%+56.65%+59.34%IMVTImmunovant-0.85%+7.64%+25.77%+10.56%-37.57%TARSTarsus Pharmaceuticals-0.55%-8.87%+22.81%+64.63%+75.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.25Hold$44.00394.10% UpsideCNTACentessa Pharmaceuticals 2.91Moderate Buy$32.3833.73% UpsideIMVTImmunovant 2.58Moderate Buy$28.7851.94% UpsideTARSTarsus Pharmaceuticals 2.50Moderate Buy$69.332.64% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, CNTA, TARS, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025AVXLAnavex Life SciencesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold10/20/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$72.00 ➝ $88.0010/20/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$72.00 ➝ $88.0010/14/2025IMVTImmunovantTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$16.0010/14/2025IMVTImmunovantWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AVXLAnavex Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CNTACentessa PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TARSTarsus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.0010/6/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.0010/1/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACNTACentessa Pharmaceuticals$6.85M473.28N/AN/A$3.05 per share7.94IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ATARSTarsus Pharmaceuticals$182.95M15.59N/AN/A$5.87 per share11.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%11/28/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest AVXL, CNTA, TARS, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TARSTarsus Pharmaceuticals-$0.35N/AN/AN/A$114.22 millionN/A11/11/2025Q3 2025CNTACentessa Pharmaceuticals-$0.39N/AN/AN/AN/AN/A11/6/2025Q2 2026IMVTImmunovant-$0.73N/AN/AN/AN/AN/A8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A8.938.93CNTACentessa Pharmaceuticals0.3210.1110.12IMVTImmunovantN/A12.3212.32TARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CNTACentessa Pharmaceuticals82.01%IMVTImmunovant47.08%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%CNTACentessa Pharmaceuticals7.09%IMVTImmunovant1.80%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableIMVTImmunovant120174.32 million171.18 millionOptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableAVXL, CNTA, TARS, and IMVT HeadlinesRecent News About These CompaniesQ3 EPS Estimate for Tarsus Pharmaceuticals Lifted by AnalystOctober 24 at 2:41 AM | americanbankingnews.comQ3 EPS Estimate for Tarsus Pharmaceuticals Raised by AnalystOctober 22 at 7:04 AM | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by TD Asset Management IncOctober 22 at 3:51 AM | marketbeat.comAllspring Global Investments Holdings LLC Sells 36,159 Shares of Tarsus Pharmaceuticals, Inc. $TARSOctober 21 at 3:24 AM | marketbeat.comHC Wainwright & Co. Maintains Tarsus Pharmaceuticals (TARS) Buy RecommendationOctober 21 at 2:34 AM | msn.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 20, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Aberdeen Group plcOctober 18, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month High - Time to Buy?October 13, 2025 | marketbeat.comWhy Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's NextOctober 9, 2025 | finance.yahoo.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)October 9, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High - What's Next?October 6, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?October 6, 2025 | zacks.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading 9.6% Higher - Time to Buy?October 3, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Should You Buy?September 30, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $332,220.00 in StockSeptember 27, 2025 | insidertrades.comBobak Azamian Sells 6,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) StockSeptember 26, 2025 | marketbeat.comTarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay OffSeptember 26, 2025 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 25, 2025 | marketbeat.com5,600 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Strs OhioSeptember 24, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVXL, CNTA, TARS, and IMVT Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$8.90 +0.17 (+1.89%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Centessa Pharmaceuticals NASDAQ:CNTA$24.21 +0.07 (+0.29%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Immunovant NASDAQ:IMVT$18.94 +0.20 (+1.07%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Tarsus Pharmaceuticals NASDAQ:TARS$67.55 -0.77 (-1.13%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
